© 2000 by European Society of Cardiology
Copyright © 2000, European Society of Cardiology
Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs
Center of Internal Medicine, Division of Cardiology, Philipps University of Marburg, Baldingerstrasse, D-35033 Marburg, Germany
* Tel.: +49-642-1286-4980; fax +49-642-470-094 brilla{at}t-online.de
Objective: In left ventricular hypertrophy (LVH) due to systemic hypertension, myocardial fibrosis is an important determinant of pathologic hypertrophy. Therefore, it is most relevant to utilize an antihypertensive regimen that permits a regression in myocardial fibrosis along with blood pressure normalization and regression of LVH. Methods: To address this issue we examined 60 Sprague—Dawley rats. We treated 16-week-old rats having established LVH and myocardial fibrosis due to 8-week renovascular hypertension (RHT) with either 6 mg/kg/day zofenopril (ZOF), 30 mg/kg/day nifedipine (NIF) or 40 mg/kg/day labetalol (LAB) for 12 weeks. Systolic arterial pressure (SAP, mmHg), left ventricular/body weight ratio (LV/BW, mg/g), and left and right ventricular collagen volume fractions (LVCVF, RVCVF, %) were obtained and compared with age/sex matched untreated rats with RHT and sham-operated controls. Results: In RHT, SAP was significantly elevated compared with controls (188±11 vs. 125±5 mmHg; P<0.001) while in each treated group SAP was normalized. LV/BW was significantly increased in RHT (2.61±0.12 mg/g; P<0.00001) while in each treated group LVH was completely regressed (P<0.002 vs. untreated RHT) with LV/BW values comparable to controls (1.82±0.03 mg/g) irrespective of the utilized antihypertensive agent. In untreated RHT, myocardial fibrosis was present in the left (LVCVF: 12.3±1.9%; P<0.0005 vs. 4.5±0.2% of controls) and right ventricles (RVCVF: 20.6±2.5%; P<0.00005 vs. 8.8±0.4% of controls). In rats treated with ZOF or NIF, LVCVF was significantly reduced to 5.6±0.4 and 5.4±0.6%, respectively (P<0.005 vs. untreated RHT), and RVCVF was decreased as well (ZOF: 11.0±0.9%; NIF: 10.4±2.4%; P<0.007 vs. untreated RHT) where no significant difference to controls remained. In contrast, treatment with LAB did not affect myocardial fibrosis where LVCVF was 9.3±1.3% and RVCVF was 19.8±2.8%, i.e., remained significantly elevated compared with controls (P<0.007). Conclusions: In rats with renovascular hypertension and hypertensive heart disease that included LVH and fibrosis, equipotent doses of ZOF, NIF, and LAB normalized arterial pressure associated with regression of LVH while only ZOF and NIF were found to regress myocardial fibrosis.
KEYWORDS ACE inhibitors; Adrenergic (ant)agonists; Antihypertensive agents; Fibrosis; Hypertension; Hypertrophy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Cuspidi, M. Ciulla, and A. Zanchetti Hypertensive myocardial fibrosis Nephrol. Dial. Transplant., January 1, 2006; 21(1): 20 - 23. [Full Text] [PDF]
|
|
|
|
 |
|
 X.-M. Gao, H. Kiriazis, X.-L. Moore, X.-H. Feng, K. Sheppard, A. Dart, and X.-J. Du Regression of pressure overload-induced left ventricular hypertrophy in mice Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2702 - H2707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J E Toblli, G Cao, G DeRosa, and P Forcada Reduced cardiac expression of plasminogen activator inhibitor 1 and transforming growth factor {beta}1 in obese Zucker rats by perindopril Heart, January 1, 2005; 91(1): 80 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Ciulla, R. Paliotti, A. Esposito, J. Diez, B. Lopez, B. Dahlof, M. G. Nicholls, R. D. Smith, L. Gilles, F. Magrini, et al. Different Effects of Antihypertensive Therapies Based on Losartan or Atenolol on Ultrasound and Biochemical Markers of Myocardial Fibrosis: Results of a Randomized Trial Circulation, August 3, 2004; 110(5): 552 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Ostrom, J. E. Naugle, M. Hase, C. Gregorian, J. S. Swaney, P. A. Insel, L. L. Brunton, and J. G. Meszaros Angiotensin II Enhances Adenylyl Cyclase Signaling via Ca2+/Calmodulin: Gq-Gs CROSS-TALK REGULATES COLLAGEN PRODUCTION IN CARDIAC FIBROBLASTS J. Biol. Chem., June 27, 2003; 278(27): 24461 - 24468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Amenta, E. Peleg, D. Tomassoni, M. Sabbatini, and T. Rosenthal Effect of Treatment With Lercanidipine on Heart of Cohen-Rosenthal Diabetic Hypertensive Rats Hypertension, June 1, 2003; 41(6): 1330 - 1335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Baicu, J. D. Stroud, V. A. Livesay, E. Hapke, J. Holder, F. G. Spinale, and M. R. Zile Changes in extracellular collagen matrix alter myocardial systolic performance Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H122 - H132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Rossi, M. Cavallin, A. S Belloni, G. Mazzocchi, G. G Nussdorfer, A. C Pessina, and S. Sartore Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension Cardiovasc Res, July 1, 2002; 55(1): 178 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Camilion de Hurtado, E. L. Portiansky, N. G. Perez, O. R. Rebolledo, and H. E. Cingolani Regression of cardiomyocyte hypertrophy in SHR following chronic inhibition of the Na+/H+ exchanger Cardiovasc Res, March 1, 2002; 53(4): 862 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. F. van Rodijnen, T. A. van Lambalgen, G.-J. Tangelder, R. P.E. van Dokkum, A. P. Provoost, and P. M. ter Wee Reduced Reactivity of Renal Microvessels to Pressure and Angiotensin II in Fawn-Hooded Rats Hypertension, January 1, 2002; 39(1): 111 - 115. [Abstract] [Full Text] [PDF]
|
|